The IGNITE Network Leadership calls for Diversity and Inclusion in the conduct of research
We call on scientific and medical communities to acknowledge and work toward eliminating the injustices perpetuated through all forms of systemic racism and discrimination, both past and present, overt and covert. We condemn eugenic beliefs, policies, and practices. While ancestry has some genetic underpinnings, race is a social construct. Thus, we recognize the consequences of racism and bias on health, healthcare, and research.
To provide more equitable care and improve health for all communities, researchers must investigate and address the causes of health disparities and include more diverse people as study leaders and participants. We commit to working hand-in-hand with patients and advocates from underserved communities to ensure that research is performed, published and applied in an ethical, unbiased, trustworthy and inclusive manner.
Striving for an equitable future, we endorse anti-racist and anti-discriminatory policies in healthcare and research. To develop a culture of understanding and inclusiveness that extends to the diverse communities we are privileged to serve, we must also foster diversity in our own institutions.
This statement and the actions that follow are the foundations of a durable process in the pursuit of health equity.
The National Human Genome Research Institute (NHGRI) invites qualified physicians, physician assistants, nurse practitioners and genetic counselors to apply to the Fellowship in Genomic Medicine Program Management. This is an NIH coalition consisting of the National Human Genome Research Institute (NHGRI), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on Minority Health and Health Disparities (NIMHD), and the All of Us Research Program in partnership with the American College of Medical Genetics (ACMG).
The goal of this fellowship is to increase the pool of physicians, physician assistants, nurse practitioners, and genetic counselors trained in managing research and implementation programs in genomic medicine. The fellowship will last 24 months, and will be located primarily in the Bethesda, Maryland area.
Application Deadline: December 1, 2020
UCSF is seeking a faculty member at the Assistant or Associate Professor rank with expertise in health services research, health economics, or a related field. Qualified applicants may also serve as the Assistant Director or Co-Director of the UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS). The Center, founded in 2008, is a global leader in developing objective evidence on the translation of personalized/precision medicine and other new technologies into clinical care and health policy. They have recently augmented our team with new faculty and a post-doctoral fellow but would like to add another faculty member in 2021.
The position focuses on developing and sustaining high-quality research that supports the mission of TRANSPERS. The faculty member will lead his/her own research projects as well as contribute to TRANSPERS focused research by leveraging and building existing expertise and developing new areas of growth. The faculty member will be integrated into the Department of Clinical Pharmacy’s teaching and service activities.
The applicant will be expected to have or obtain grant funding, but there is initial funding available for 1-2 years. This position also offers the possibility for a joint affiliate appointment in the UCSF Philip R. Lee Institute for Health Policy Studies as well as other UCSF centers.
Interested candidates should apply online at: https://aprecruit.ucsf.edu/JPF02493 with a cover letter, a curriculum vitae, statement of research and teaching, statement of contributions to diversity, and the names, titles, and contact information for three references. For further information, you may contact Kathryn Phillips at Kathryn.Ph[email protected]. This position has been determined to be exempt for the UCSF-wide hiring freeze.
Deadline for applications: Nov. 9 (start date is negotiable). Applications received by Sept 30 will receive priority consideration
IGNITE hit a major milestone on July 10, 2020: The University of Florida randomized the first patient in to the GUARDD-US pragmatic clinical trial.
Genetic testing to Understand Renal Disease Disparities across the US (GUARDD-US) will investigate the results of apolipoprotein L1 (APOL1) genotyping in an African American population.
The primary outcome is systolic blood pressure (SBP) at three months comparing patients with high-risk APOL1 variants (positives) versus no high-risk variants (negatives). The co-primary outcome is three-month SBP in positives versus those receiving delayed testing. Secondary outcomes include renal disease testing, and psycho-behavioral factors. The team will re-randomize APOL1 negative patients to a genotype-guided approach to anti-hypertensive therapy versus usual care and compare three-month SBP.